{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:13:43Z","timestamp":1789586023195,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.xphs.2017.09.018","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T01:00:14Z","timestamp":1507770014000},"page":"638-646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Optimization of a Vaginal Suppository Formulation to Deliver SHetA2 as a Novel Treatment for Cervical Dysplasia"],"prefix":"10.1016","volume":"107","author":[{"given":"Sanjida","family":"Mahjabeen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manolya K.","family":"Hatipoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris M.","family":"Benbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucila","family":"Garcia-Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.xphs.2017.09.018_bib1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.xphs.2017.09.018_bib2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ncponc0984","article-title":"Human papillomavirus in cervical and head-and-neck cancer","volume":"5","author":"Psyrri","year":"2008","journal-title":"Nat Clin Prac Oncol"},{"issue":"1","key":"10.1016\/j.xphs.2017.09.018_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.16.1.1-17.2003","article-title":"Human papillomavirus and cervical cancer","volume":"16","author":"Burd","year":"2003","journal-title":"Clin Microbiol Rev"},{"issue":"8","key":"10.1016\/j.xphs.2017.09.018_bib4","doi-asserted-by":"crossref","first-page":"946","DOI":"10.5858\/2003-127-946-FTDFTA","article-title":"Findings to date from the ASCUS-LSIL triage study (ALTS)","volume":"127","author":"Schiffman","year":"2003","journal-title":"Arch Pathol Lab Med"},{"issue":"7","key":"10.1016\/j.xphs.2017.09.018_bib5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrclinonc.2015.104","article-title":"Cervical cancer: squamocolumnar junction ablation\u2014tying up loose ends?","volume":"12","author":"Herfs","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"16","key":"10.1016\/j.xphs.2017.09.018_bib6","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.1158\/0008-5472.CAN-09-0913","article-title":"Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells","volume":"69","author":"Masamha","year":"2009","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.xphs.2017.09.018_bib7","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1210\/en.2004-0959","article-title":"Minireview: cyclin D1: normal and abnormal functions","volume":"145","author":"Fu","year":"2004","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.xphs.2017.09.018_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/mp.51.1.1","article-title":"Cyclin D1 and human neoplasia","volume":"51","author":"Donnellan","year":"1998","journal-title":"Mol Pathol"},{"issue":"9","key":"10.1016\/j.xphs.2017.09.018_bib9","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1158\/1940-6207.CAPR-13-0171","article-title":"Chemoprevention of colon and small intestinal tumorigenesis in APC(min\/+) mice by SHetA2 (NSC721689) without toxicity","volume":"6","author":"Benbrook","year":"2013","journal-title":"Cancer Prev Res (Phila)"},{"issue":"5","key":"10.1016\/j.xphs.2017.09.018_bib10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10637-005-2901-5","article-title":"Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists","volume":"23","author":"Benbrook","year":"2005","journal-title":"Invest New Drugs"},{"issue":"3","key":"10.1016\/j.xphs.2017.09.018_bib11","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3109\/01480545.2012.710632","article-title":"Oral toxicity and pharmacokinetic studies of SHetA2, a new chemopreventive agent, in rats and dogs","volume":"36","author":"Kabirov","year":"2013","journal-title":"Drug Chem Toxicol"},{"issue":"5","key":"10.1016\/j.xphs.2017.09.018_bib12","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.tiv.2005.10.002","article-title":"Organotypic human vaginal-ectocervical tissue model for irritation studies of spermicides, microbicides, and feminine-care products","volume":"20","author":"Ayehunie","year":"2006","journal-title":"Toxicol In\u00a0Vitro"},{"issue":"7","key":"10.1016\/j.xphs.2017.09.018_bib13","doi-asserted-by":"crossref","first-page":"13226","DOI":"10.3390\/molecules200713226","article-title":"The enhanced inhibitory effect of different antitumor agents in self-microemulsifying drug delivery systems on human cervical cancer HeLa cells","volume":"20","author":"Ujhelyi","year":"2015","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.xphs.2017.09.018_bib14","doi-asserted-by":"crossref","first-page":"475","DOI":"10.4103\/1735-9066.193393","article-title":"A\u00a0survey of the therapeutic effects of Vitamin E suppositories on vaginal atrophy in postmenopausal women","volume":"21","author":"Parnan Emamverdikhan","year":"2016","journal-title":"Iran J Nurs Midwifery Res"},{"issue":"2","key":"10.1016\/j.xphs.2017.09.018_bib15","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3109\/10717544.2014.928760","article-title":"Advanced topical drug delivery system for the management of vaginal candidiasis","volume":"23","author":"Johal","year":"2016","journal-title":"Drug Deliv"},{"issue":"6","key":"10.1016\/j.xphs.2017.09.018_bib16","first-page":"111","article-title":"Single-dose therapy for genitourinary infections","volume":"36","author":"Fox","year":"1987","journal-title":"Am Fam Physician"},{"issue":"5","key":"10.1016\/j.xphs.2017.09.018_bib17","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/mmy\/myv017","article-title":"A\u00a0randomized clinical trial of the efficacy and safety of terconazole vaginal suppository versus oral fluconazole for treating severe vulvovaginal candidiasis","volume":"53","author":"Li","year":"2015","journal-title":"Med Mycol"},{"issue":"4","key":"10.1016\/j.xphs.2017.09.018_bib18","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s10637-008-9175-7","article-title":"Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in\u00a0vitro and in\u00a0vivo","volume":"27","author":"Myers","year":"2009","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.xphs.2017.09.018_bib19","series-title":"OECD, Test No. 107: Partition Coefficient (n-octanol\/water): Shake Flask Method","year":"1995"},{"issue":"6","key":"10.1016\/j.xphs.2017.09.018_bib20","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/jps.2600560602","article-title":"Potentiometric determination of dissociation constants","volume":"56","author":"Benet","year":"1967","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2017.09.018_bib21","series-title":"Supplement to IV\/6","first-page":"520","article-title":"Dielectric constant of the mixture (1) water; (2) ethanol","author":"Wohlfarth","year":"2008"},{"key":"10.1016\/j.xphs.2017.09.018_bib23","series-title":"Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems","author":"Allen","year":"2011"},{"issue":"4","key":"10.1016\/j.xphs.2017.09.018_bib24","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jpba.2011.01.008","article-title":"Mixture experiment methods in the development and optimization of microemulsion formulations","volume":"55","author":"Furlanetto","year":"2011","journal-title":"J\u00a0Pharm Biomed Anal"},{"issue":"2","key":"10.1016\/j.xphs.2017.09.018_bib25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1472-9792(08)70024-6","article-title":"Rifampin","volume":"88","year":"2008","journal-title":"Tuberculosis"},{"issue":"5","key":"10.1016\/j.xphs.2017.09.018_bib26","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/0731-7085(89)80220-1","article-title":"Investigation of the relationship between melting-related parameters and in\u00a0vitro drug release from vaginal suppositories","volume":"7","author":"Bergren","year":"1989","journal-title":"J\u00a0Pharm Biomed Anal"},{"issue":"5","key":"10.1016\/j.xphs.2017.09.018_bib27","doi-asserted-by":"crossref","first-page":"640","DOI":"10.4103\/0250-474X.45405","article-title":"Formulation and evaluation of tramadol hydrochloride rectal suppositories","volume":"70","author":"Saleem","year":"2008","journal-title":"Indian J Pharm Sci"},{"key":"10.1016\/j.xphs.2017.09.018_bib28","series-title":"International Pharmacopoeia","volume":"5","year":"2003"},{"issue":"5","key":"10.1016\/j.xphs.2017.09.018_bib29","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s00125-013-2846-8","article-title":"Mouse strain-dependent variation in obesity and glucose homeostasis in response to high-fat feeding","volume":"56","author":"Montgomery","year":"2013","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.xphs.2017.09.018_bib30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.14227\/DT180311P15","article-title":"Simulated biological fluids with possible application in dissolution testing","volume":"18","author":"Marques","year":"2011","journal-title":"Dissolut Technol"},{"issue":"1","key":"10.1016\/j.xphs.2017.09.018_bib31","first-page":"28","article-title":"2D DIGE proteomic analysis of multidrug resistant and susceptible clinical Mycobacterium tuberculosis isolates","volume":"4","author":"Phong","year":"2014","journal-title":"J\u00a0Integr Omics"},{"issue":"7","key":"10.1016\/j.xphs.2017.09.018_bib33","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/jnci\/86.7.539","article-title":"Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial","volume":"86","author":"Meyskens","year":"1994","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.xphs.2017.09.018_bib34","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/AOG.0b013e31825bc6e8","article-title":"Treatment of cervical intraepithelial neoplasia with topical imiquimod: a randomized controlled trial","volume":"120","author":"Grimm","year":"2012","journal-title":"Obstet Gynecol"},{"issue":"4 Pt 2","key":"10.1016\/j.xphs.2017.09.018_bib35","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S0190-9622(86)70240-5","article-title":"Clinical experience with topical tretinoin in the treatment of cervical dysplasia","volume":"15","author":"Meyskens","year":"1986","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.xphs.2017.09.018_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijgo.2007.10.023","article-title":"Imiquimod for treatment of vulvar and vaginal intraepithelial neoplasia","volume":"101","author":"Iavazzo","year":"2008","journal-title":"Int J Gynaecol Obstet"},{"issue":"1","key":"10.1016\/j.xphs.2017.09.018_bib37","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12885-017-3108-9","article-title":"Preliminary stop of the TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC) trial","volume":"17","author":"Koeneman","year":"2017","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.xphs.2017.09.018_bib38","doi-asserted-by":"crossref","first-page":"42.e1","DOI":"10.1016\/j.ajog.2011.06.105","article-title":"Randomized clinical trial of imiquimod: an adjunct to treating cervical dysplasia","volume":"206","author":"Pachman","year":"2012","journal-title":"Am J Obstet Gynecol"},{"issue":"15","key":"10.1016\/j.xphs.2017.09.018_bib39","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.2165\/00003495-200767150-00006","article-title":"Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions","volume":"67","author":"Wagstaff","year":"2007","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.xphs.2017.09.018_bib40","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF02853158","article-title":"Potential patient preference for 3-day treatment of bacterial vaginosis: responses to new suppository form of clindamycin","volume":"17","author":"Broumas","year":"2000","journal-title":"Adv Ther"},{"issue":"3 Pt 1","key":"10.1016\/j.xphs.2017.09.018_bib41","first-page":"414","article-title":"Comparison of 0.8% and 1.6% terconazole cream in severe vulvovaginal candidiasis","volume":"76","author":"Schmitt","year":"1990","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.xphs.2017.09.018_bib42","series-title":"Pharmaceutical Emulsions: A Drug Developers Toolbag","author":"Sarker","year":"2013"},{"key":"10.1016\/j.xphs.2017.09.018_bib43","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2015.04.017","article-title":"Vaginal drug distribution modeling","volume":"92","author":"Katz","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"10.1016\/j.xphs.2017.09.018_bib44","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0169-409X(92)90008-E","article-title":"(D) Routes of delivery: case studies","volume":"8","author":"Richardson","year":"1992","journal-title":"Adv Drug Deliv Rev"},{"issue":"suppl 1","key":"10.1016\/j.xphs.2017.09.018_bib45","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0020-7292(00)00348-9","article-title":"Topical treatment of vaginal candidosis with sertaconazole and econazole sustained-release suppositories","volume":"71","author":"Dellenbach","year":"2000","journal-title":"Int J Gynecol Obstet"},{"issue":"4","key":"10.1016\/j.xphs.2017.09.018_bib46","first-page":"495","article-title":"Application of pharmaceutical profiling assays for optimization of drug-like properties","volume":"8","author":"Di","year":"2005","journal-title":"Curr Opin Drug Discov Devel"},{"issue":"7","key":"10.1016\/j.xphs.2017.09.018_bib47","first-page":"1294","article-title":"Cross-species comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-HPV16 transgenic mice","volume":"57","author":"Smith-McCune","year":"1997","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.xphs.2017.09.018_bib48","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00126839-200405050-00001","article-title":"Correlations between factors determining the pharmacokinetics and antiviral activity of HIV-1 non-nucleoside reverse transcriptase inhibitors of the diaryltriazine and diarylpyrimidine classes of compounds","volume":"5","author":"Lewi","year":"2004","journal-title":"Drugs R D"},{"issue":"6","key":"10.1016\/j.xphs.2017.09.018_bib49","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3109\/03639045.2013.788011","article-title":"Sildenafil vaginal suppositories: preparation, characterization, in\u00a0vitro and in\u00a0vivo evaluation","volume":"40","author":"Shanmugam","year":"2014","journal-title":"Drug Dev Ind Pharm"},{"issue":"6","key":"10.1016\/j.xphs.2017.09.018_bib50","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0015-0282(16)57594-3","article-title":"Danazol concentrations in ovary, uterus, and serum and their effect on the hypothalamic-pituitary-ovarian axis during vaginal administration of a danazol suppository","volume":"63","author":"Mizutani","year":"1995","journal-title":"Fertil Steril"},{"issue":"1","key":"10.1016\/j.xphs.2017.09.018_bib51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11095-004-9004-4","article-title":"Predicting drug disposition via application of BCS: transport\/absorption\/elimination interplay and development of a biopharmaceutics drug disposition classification system","volume":"22","author":"Wu","year":"2005","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/j.xphs.2017.09.018_bib52","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/1535-7163.MCT-08-1069","article-title":"Development of flexible heteroarotinoids (fex-hets) for kidney cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Molecular Cancer Therapeutics"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354917306755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354917306755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T09:26:02Z","timestamp":1659605162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354917306755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0022354917306755"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2017.09.018","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimization of a Vaginal Suppository Formulation to Deliver SHetA2 as a Novel Treatment for Cervical Dysplasia","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2017.09.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}